Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Gastroenterology | Immunology/Infectious Diseases
Disease Category: Hepatitis
Trial Information
Comparison of Peg-Intron 1.5 ug/kg/wk Plus Rebetol vs. Peg-Intron 1 ug/kg/wk Plus Rebetol vs. Pegasys 180 ug/wk Plus Copegus in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1 [P03471]
This study is for patients who have chronic hepatitis C that
have never been treated with interferons or ribavirin. Study
participants will receive either Peg-Intron plus Rebetol or Pegasys
plus Copegus.
All study medications and most procedures will be provided at no
cost. There will be 15 clinic visits over 1 1/2 years.
No Compensation Provided
Patient Inclusion/Exclusion Criteria:
You may be eligible to participate if you
-are male or female 18-70 years old
-have been diagnosed with chronic hepatitis C
-meet additional criteria
You will not be able to participate if you
-have been treated with interferon or ribavirin
-are pregnant or breastfeeding
-are HIV positive
-have a history of cancer within the last 5 years
-have had an organ transplant
Alison Uriel, MD
Mount Sinai Medical Center
One Gustave L. Levy Place
New York, NY 10029
Phone: 212-241-8903
Fax: 212-241-4465
EMail: alison.uriel@mountsinai.org
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
